Latest research developments have shed light on the risk factors that contribute to metabolic complications, involving both genetic and environmental factors, potentially integrated by epigenetic mechanisms. Distinct epigenetic variations in immune cells are frequently observed in metabolic diseases characterized by highly specific inflammatory responses in many diseases such as obesity, type 2 diabetes mellitus or in many types of cancers etc. Furthermore, these changes, in turn, are associated with alterations in the phenotype, function and traffic patterns of these cells, giving rise to different clinical phenotypes. Understanding the epigenetic signatures that regulate the molecular bases of these types of diseases is the first step in the development of effective therapeutic strategies associated with metabolic disorders.
The aim of this Research Topic is to provide up-to-date information on the clinical utility and diagnostic performance of different epigenetic biomarkers, as well as to shed new light on the molecular basis of inflammatory and metabolic diseases.
Our goal is to offer new discoveries about epigenetics in the field of inflammatory and metabolic diseases, improving current knowledge and opening new therapeutic avenues. Furthermore, we aim to showcase new discoveries into associations between genes and human phenotypes affecting high and low prevalence diseases.
We will consider Original Research, Brief Research Report, and Review articles covering (but not limited to) the following themes:
• Identification of novel epigenetic roles and their impact on the pathophysiology of human phenotypes affecting patients with inflammatory and metabolic disorders.
• Novel findings exploring the role of epigenetics known to be associated with inflammatory and metabolic disorders.
• New insights about the molecular basis of inflammatory and metabolic diseases.
• Clinical utility and molecular risk factors affecting the diagnosis and prognosis of inflammatory and metabolic diseases.
Latest research developments have shed light on the risk factors that contribute to metabolic complications, involving both genetic and environmental factors, potentially integrated by epigenetic mechanisms. Distinct epigenetic variations in immune cells are frequently observed in metabolic diseases characterized by highly specific inflammatory responses in many diseases such as obesity, type 2 diabetes mellitus or in many types of cancers etc. Furthermore, these changes, in turn, are associated with alterations in the phenotype, function and traffic patterns of these cells, giving rise to different clinical phenotypes. Understanding the epigenetic signatures that regulate the molecular bases of these types of diseases is the first step in the development of effective therapeutic strategies associated with metabolic disorders.
The aim of this Research Topic is to provide up-to-date information on the clinical utility and diagnostic performance of different epigenetic biomarkers, as well as to shed new light on the molecular basis of inflammatory and metabolic diseases.
Our goal is to offer new discoveries about epigenetics in the field of inflammatory and metabolic diseases, improving current knowledge and opening new therapeutic avenues. Furthermore, we aim to showcase new discoveries into associations between genes and human phenotypes affecting high and low prevalence diseases.
We will consider Original Research, Brief Research Report, and Review articles covering (but not limited to) the following themes:
• Identification of novel epigenetic roles and their impact on the pathophysiology of human phenotypes affecting patients with inflammatory and metabolic disorders.
• Novel findings exploring the role of epigenetics known to be associated with inflammatory and metabolic disorders.
• New insights about the molecular basis of inflammatory and metabolic diseases.
• Clinical utility and molecular risk factors affecting the diagnosis and prognosis of inflammatory and metabolic diseases.
